Only 25% of multidrug-resistant tuberculosis (MDR-TB) cases are currently diagnosed. Line
probe assays (LPAs) enable rapid drug-susceptibility testing for rifampicin (RIF) and …

BACKGROUND: Drug-resistant tuberculosis (TB), especially multidrug-resistant (MDR,
resistance to rifampicin and isoniazid) disease, is associated with a worse patient outcome …

Objectives Phenotypic drug susceptibility testing for prediction of tuberculosis (TB) drug
resistance is slow and unreliable, limiting individualized therapy and monitoring of national …

Background The objectives of the study were to compare the performance of line probe
assay (GenoType MTBDR plus) with solid culture method for an early diagnosis of multidrug …

Background There is an urgent demand for rapid and accurate drug-susceptibility testing for
the detection of multidrug-resistant tuberculosis. The GenoType MTBDR plus assay is a …

Background. Diagnosis of drug resistance and timely initiation of multidrug-resistant (MDR)
tuberculosis therapy are essential to reduce transmission and improve patient outcomes. We …

The recognition that drug-resistant tuberculosis (DR-TB) poses a major threat to global
tuberculosis (TB) control efforts has catalysed the development of new and urgently needed …

Most cases of multidrug-resistant (MDR) tuberculosis (TB) are never diagnosed (328,300 of
the∼ 490,000 cases in 2016 were missed). The Xpert MTB/RIF assay detects resistance …

Abstract Most Mycobacterium tuberculosis (Mtb) resistant to rifampicin (RIF) has mutations in
the rpoB gene, while most Mtb resistant to isoniazid (INH) has mutations in the katG gene or …

Limited performance data from line probe assays (LPAs), nucleic acid tests used for the
rapid diagnosis of tuberculosis (TB), nontuberculosis mycobacteria (NTM), and …